A First Report of Radioembolization for Hepatic Metastases From Ocular Melanoma

REFERENCES

• Singh A. D., Bergman L., Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005; 18(1)75–84, viii
   PubMedGoogle Scholar
• Rietschel P., Panageas K. S., Hanlon C., Patel A., Abramson D. H., Chapman P. B. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005; 23(31)8076–8080
   PubMed Web of Science ®Google Scholar
• Diener-West M., Earle J. D., Fine S. L., Hawkins B. S., Moy C. S., Reynolds S. M., Schachat A. P., Straatsma B. R. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119(7)969–982
   PubMed Web of Science ®Google Scholar
• Damato B. Treatment of primary intraocular melanoma. Expert Rev Anticancer Ther 2006; 6(4)493–506
   PubMed Web of Science ®Google Scholar
• Gragoudas E., Li W., Goitein M., Lane A. M., Munzenrider J. E., Egan K. M. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002; 120(12)1665–1671
   PubMed Web of Science ®Google Scholar
• The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124(12)1684–1693
   PubMed Web of Science ®Google Scholar
• Diener-West M., Reynolds S. M., Agugliaro D. J., Caldwell R., Cumming K., Earle J. D., Hawkins B. S., Hayman J. A., Jaiyesimi I., Jampol L. M., Kirkwood J. M., Koh W. J., Robertson D. M., Shaw J. M., Straatsma B. R., Thoma J. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123(12)1639–1643
   PubMed Web of Science ®Google Scholar
• Hawkins B. S. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 2004; 138(6)936–951
   PubMed Web of Science ®Google Scholar
• Melia M., Moy C. S., Reynolds S. M., Cella D., Murray T. G., Hovland K. R., Hayman J. A., Mangione C. M. Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS report No. 2. Arch Ophthalmol 2003; 121(7)1010–1020
   PubMed Web of Science ®Google Scholar
• Trends i n. size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS report no. 20. Arch Ophthalmol 2003; 121(8)1156–1162
   PubMed Web of Science ®Google Scholar
• Peters S., Voelter V., Zografos L., Pampallona S., Popescu R., Gillet M., Bosshard W., Fiorentini G., Lotem M., Weitzen R., Keilholz U., Humblet Y., Piperno-Neumann S., Stupp R., Leyvraz S. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17(4)578–583
   PubMed Web of Science ®Google Scholar
• Gragoudas E. S., Egan K. M., Seddon J. M., Glynn R. J., Walsh S. M., Finn S. M., Munzenrider J. E., Spar M. D. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98(3)383–389, discussion 390
   PubMed Web of Science ®Google Scholar
• Kath R., Hayungs J., Bornfeld N., Sauerwein W., Hoffken K., Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72(7)2219–2223
   PubMed Web of Science ®Google Scholar
• Feldman E. D., Pingpank J. F., Alexander H. R., Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11(3)290–297
   PubMed Web of Science ®Google Scholar
• Carrasco C. H., Wallace S., Charnsangavej C., Papadopoulos N. E., Patt Y. Z., Mavligit G. M. Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA 1986; 255(22)3152–3154
   Google Scholar
• Mavligit G. M., Charnsangavej C., Carrasco C. H., Patt Y. Z., Benjamin R. S., Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988; 260(7)974–976
   PubMed Web of Science ®Google Scholar
• Alexander H. R., Libutti S. K., Bartlett D. L., Puhlmann M., Fraker D. L., Bachenheimer L. C. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6(8)3062–3070
   PubMed Web of Science ®Google Scholar
• Bedikian A. Y., Legha S. S., Mavligit G., Carrasco C. H., Khorana S., Plager C., Papadopoulos N., Benjamin R. S. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76(9)1665–1670
   Google Scholar
• Rivoire M., Kodjikian L., Baldo S., Kaemmerlen P., Negrier S., Grange J. D. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 2005; 12(6)422–428
   PubMed Web of Science ®Google Scholar
• Ariel I. M. Radioactive isotopes for adjuvant cancer therapy. Arch Surg 1964; 89: 244–249
   PubMed Web of Science ®Google Scholar
• Blanchard R. J., Grotenhuis I., LaFave J. W. Treatment of experimental tumors: utilization of radioactive microspheres. Arch Surg 1964; 89: 406
   PubMed Web of Science ®Google Scholar
• Blanchard R. J., LaFave J. W., Kim Y. S. Treatment of patients with advanced cancer using Y-90 microspheres. Cancer 1965; 18: 375
   PubMed Web of Science ®Google Scholar
• Simon N., Warner R. R., Baron M. G., Rudavsky A. Z. Intra-arterial irradiation of carcinoid tumors of the liver. Am J Roentgenol Radium Ther Nucl Med 1968; 102(3)552–561
   PubMedGoogle Scholar
• Breedis C., Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969–984
   PubMed Web of Science ®Google Scholar
• Gray B., Van Hazel G., Hope M., Burton M. A., Moroz P., Anderson J. E., Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12(12)1711–1720
   Google Scholar
• Kennedy A. S., Coldwell D., Nutting C., Murthy R., Wertman D. E., Jr., Loehr S. P., Overton C., Meranze S., Niedzwiecki J., Sailer S. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65(2)412–425
   PubMed Web of Science ®Google Scholar
• Salem R., Thurston K. G. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006; 17(10)1571–1593
   PubMed Web of Science ®Google Scholar
• Dancey J. E., Shepherd F. A., Paul K., Sniderman K. W., Houle S., Gabrys J., Hendler A. L., Goin J. E. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres [In Process Citation]. J Nucl Med 2000; 41(10)1673–1681
   PubMed Web of Science ®Google Scholar
• Lau W. Y., Leung W. T., Ho S., Leung N. W., Chan M., Lin J., Metreweli C., Johnson P., Li A. K. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994; 70(5)994–999
   PubMed Web of Science ®Google Scholar
• Salem R., Lewandowski R. J., Atassi B., Gordon S. C., Gates V. L., Barakat O., Sergie Z., Wong C. Y., Thurston K. G. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16(12)1627–1639
   PubMed Web of Science ®Google Scholar
• Kennedy A. S., Dezarn W. A., McNeillie P., Coldwell D., Nutting C., Carter D., Murthy R., Rose S., Warner R. R., Liu D., Palmedo H., Overton C., Jones B., Salem R. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31(3)271–279
   PubMed Web of Science ®Google Scholar
• Kennedy A. S., Dezarn W. A., McNeillie P., Overton C., England M., Sailer S. L. Fractionation, dose selection, and response of hepatic metastases of neuroendocrine tumors after 90 Y-microsphere brachytherapy. Brachytherapy 2006; 5: 103–104
   Google Scholar
• Kennedy A. S., Van Echo D. A., Murthy R. Hepatic artery brachytherapy for neuroendocrine carcinoma. Regul Pept 2002; 108: 32–4
   Google Scholar
• Kennedy A. S., Murthy R., Sarfaraz M., Yu C., Line B. R., Ma L., Van Echo D. A. Outpatient hepatic artery brachytherapy for primary and secondary hepatic malignancies. Radiology 2001; 221(P(Suppl.))468–1
   Google Scholar
• Salem R., Thurston K. G. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol 2006; 17(9)1425–1439
   PubMed Web of Science ®Google Scholar
• Salem R., Thurston K. G. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17(8)1251–1278
   PubMed Web of Science ®Google Scholar
• Kennedy A., Nag S., Salem R., Murthy R., McEwan A. J., Nutting C., Benson A., Espat J., 3rd, Bilbao J. I., Sharma R. A., Thomas J. P., Coldwell D. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68(1)13–23
   PubMed Web of Science ®Google Scholar
• Lewandowski R. J., Sato K. T., Atassi B., Ryu R. K., Nemcek A. A., Jr., Kulik L., Geschwind J. F., Murthy R., Rilling W., Liu D., Bester L., Bilbao J. I., Kennedy A. S., Omary R. A., Salem R. Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30(4)571–592
   PubMed Web of Science ®Google Scholar
• Salem R., Thurston K. G. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17(8)1251–1278
   PubMed Web of Science ®Google Scholar
• Goin J. E., Dancey J. E., Roberts C. A., Leung D. A., Soulen M. C. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med 2004; 3(1)49–56
   Google Scholar
• Goin J. E., Salem R., Carr B. I., Dancey J. E., Soulen M. C., Geschwind J. F., Goin K., Van Buskirk M., Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16((2 Pt. 1))205–213
   PubMed Web of Science ®Google Scholar
• Goin J. E., Salem R., Carr B. I., Dancey J. E., Soulen M. C., Geschwind J. F., Goin K., Van Buskirk M., Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005; 16((2 Pt. 1))195–203
   PubMed Web of Science ®Google Scholar
• Kennedy A. S., Nutting C., Coldwell D., Gaiser J., Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60(5)1552–1563
   PubMed Web of Science ®Google Scholar
• Diener-West M., Reynolds S. M., Agugliaro D. J., Caldwell R., Cumming K., Earle J. D., Green D. L., Hawkins B. S., Hayman J., Jaiyesimi I., Kirkwood J. M., Koh W. J., Robertson D. M., Shaw J. M., Thoma J. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 2004; 22(12)2438–2444
   PubMed Web of Science ®Google Scholar
• Gilson M. M., Diener-West M., Hawkins B. S. Comparison of survival among eligible patients not enrolled versus enrolled in the Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. Ophthalm Epidemiol 2007; 14(4)251–257
   PubMed Web of Science ®Google Scholar
• Jampol L. M., Moy C. S., Murray T. G., Reynolds S. M., Albert D. M., Schachat A. P., Diddie K. R., Engstrom R. E., Jr., Finger P. T., Hovland K. R., Joffe L., Olsen K. R., Wells C. G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002; 109(12)2197–2206
   Google Scholar
• Margo C. E. The Collaborative Ocular Melanoma Study: an overview. Cancer Control 2004; 11(5)304–309
   PubMedGoogle Scholar
• Melia M., Moy C. S., Reynolds S. M., Hayman J. A., Murray T. G., Hovland K. R., Earle J. D., Kurinij N., Dong L. M., Miskala P. H., Fountain C., Cella D., Mangione C. M. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Arch Ophthalmol 2006; 124(2)226–238
   PubMed Web of Science ®Google Scholar
• Mobley R. Y., Moy C. S., Reynolds S. M., Diener-West M., Newhouse M. M., Kerman J. S., Hawkins B. S. Time trends in personnel certification and turnover in the Collaborative Ocular Melanoma Study. Clin Trials 2004; 1(4)377–386
   PubMedGoogle Scholar
• Lewandowski R. J., Thurston K. G., Goin J. E., Wong C. Y., Gates V. L., Van Buskirk M., Geschwind J. F., Salem R. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16(12)1641–1651
   PubMed Web of Science ®Google Scholar
• Miller F. H., Keppke A. L., Reddy D., Huang J., Jin J., Mulcahy M. F., Salem R. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007; 188(3)776–783
   PubMed Web of Science ®Google Scholar
• Wong C. Y., Savin M., Sherpa K. M., Qing F., Campbell J., Gates V. L., Lewandowski R. J., Cheng V., Thie J., Fink-Bennett D., Nagle C., Salem R. Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma. Cancer Biother Radiopharm 2006; 21(4)305–313
   PubMed Web of Science ®Google Scholar
• Helton W. S. Ocular melanoma metastatic to the liver: the role of surgery in multimodality therapy. Ann Surg Oncol 2004; 11(3)242–244
   PubMed Web of Science ®Google Scholar
• Hsueh E. C., Essner R., Foshag L. J., Ye X., Wang H. J., Morton D. L. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 2004; 100(1)122–129
   PubMed Web of Science ®Google Scholar
• Agarwala S. S., Panikkar R., Kirkwood J. M. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 2004; 14(3)217–222
   PubMed Web of Science ®Google Scholar
• Vogl T., Eichler K., Zangos S., Herzog C., Hammerstingl R., Balzer J., Gholami A. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007; 133(3)177–184
   PubMed Web of Science ®Google Scholar
• Patel K., Sullivan K., Berd D., Mastrangelo M. J., Shields C. L., Shields J. A., Sato T. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005; 15(4)297–304
   PubMed Web of Science ®Google Scholar
• Grover A., Alexander H. R., Jr. The past decade of experience with isolated hepatic perfusion. Oncologist 2004; 9(6)653–664
   PubMed Web of Science ®Google Scholar